The DOI matches its Crossref record; 218 of the 218 references it cites were found in a registry or an index.
miRNA-based biomarkers, therapies, and resistance in Cancer
Open accessAbstract
MicroRNAs (miRNAs), small non-coding RNAs (ncRNAs) of about 22 nucleotides in size, play important roles in gene regulation, and their dysregulation is implicated in human diseases including cancer. A variety of miRNAs could take roles in the cancer progression, participate in the process of tumor immune, and function with miRNA sponges. During the last two decades, the connection between miRNAs and various cancers has been widely researched. Based on evidence about miRNA, numerous potential cancer biomarkers for the diagnosis and prognosis have been put forward, providing a new perspective on cancer screening. Besides, there are several miRNA-based therapies among different cancers being conducted, advanced treatments such as the combination of synergistic strategies and the use of complementary miRNAs provide significant clinical benefits to cancer patients potentially. Furthermore, it is demonstrated that many miRNAs are engaged in the resistance of cancer therapies with their complex underlying regulatory mechanisms, whose comprehensive cognition can help clinicians and improve patient prognosis. With the belief that studies about miRNAs in human cancer would have great clinical implications, we attempt to summarize the current situation and potential development prospects in this review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
10 retracted
Items 201–218 of 218
Sherman, E. J., Mitchell, D. C., & Garner, A. L. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ac119.010419 · Cited by 33
Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma
Fujishita, T., Kojima, Y., Kajino‐Sakamoto, R., Taketo, M. M., & Aoki, M. (2017) · Oncogene · doi:10.1038/onc.2017.242 · Cited by 30
Epithelial‐mesenchymal transition and microRNAs: Challenges and future perspectives in oral cancer
Domingues, C., Serambeque, B., Laranjo, M., Marto, C. M., Veiga, F., Sarmento‐Ribeiro, A. B., Figueiras, A., Botelho, M. F., & Dourado, M. (2018) · Head & Neck · doi:10.1002/hed.25381 · Cited by 30
Cao, Y. Q., Green, K., Quattlebaum, S. C., Milam, B., Lu, L., Gao, D., He, H., Li, N., Gao, L., Hall, F., et al. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0470-7 · Cited by 27
Okazaki, J., Tanahashi, T., Sato, Y., Miyoshi, J., Nakagawa, T., Kimura, T., Miyamoto, H., Fujino, Y., Nakamura, F., Takehara, M., et al. (2019) · Digestion · doi:10.1159/000503225 · Cited by 25
MiR-138 indirectly regulates the MDR1 promoter by NF-κB/p65 silencing
Requenez‐Contreras, J. L., Lopez‐Castillejos, E. S., Hernández-Flores, R., Moreno‐Eutímio, M. A., Granados-Riveron, J. T., Martinez‐Ruíz, G. U., & Aquino‐Jarquín, G. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.01.168 · Cited by 24
Recently Evolved Tumor Suppressor Transcript TP73-AS1 Functions as Sponge of Human-Specific miR-941
Hu, H., Liu, J.-M., Hu, Z., Jiang, X., Yang, X., Li, J., Zhang, Y., Yu, H., & Khaitovich, P. (2018) · Molecular Biology and Evolution · doi:10.1093/molbev/msy022 · Cited by 24
Self-citationmiR‑1271 enhances the sensitivity of colorectal cancer cells to cisplatin
Yao, H., Sun, Q., & Zhu, J. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7501 · Cited by 24
Zarringhalam, K., Tay, Y., Kulkarni, P. R., Bester, A. C., Pandolfi, P. P., & Kulkarni, R. (2017) · Scientific Reports · doi:10.1038/s41598-017-08209-1 · Cited by 22
Dual Epigenetic Regulation of ERα36 Expression in Breast Cancer Cells
Thiébaut, C., Chesnel, A., Merlin, J., Chesnel, M., Leroux, A., Harlé, A., & Dumond, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112637 · Cited by 22
MicroRNA-210 May Be a Preoperative Biomarker of Malignant Pheochromocytomas and Paragangliomas
Ruff, S. M., Ayabe, R. I., Malekzadeh, P., Good, M. L., Wach, M. M., Gonzales, M. K., Tirosh, A., Nilubol, N., Pacák, K., Kebebew, E., et al. (2019) · Journal of Surgical Research · doi:10.1016/j.jss.2019.04.086 · Cited by 22
Orellana, E. A., Li, C., Lisevick, A. B., & Kasinski, A. L. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1634956 · Cited by 21
Wang, L. Q., Kumar, S. K., Calin, G. A., Li, Z., & Chim, C. S. (2020) · British Journal of Haematology · doi:10.1111/bjh.16517 · Cited by 21
Urinary Excretion of MicroRNA-126 Is a Biomarker for Hemangioma Proliferation
Biswas, A., Pan, X. J., Meyer, M., Khanna, S., Roy, S., Pearson, G. D. N., Kirschner, R. E., Witman, P. M., Faith, E. F., Sen, C. K., et al. (2017) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000003349 · Cited by 13
A Fast Parameter Identification Framework for Personalized Pharmacokinetics
Yang, C., Tavassolian, N., Haddad, W. M., Bailey, J. M., & Gholami, B. (2019) · Scientific Reports · doi:10.1038/s41598-019-50810-z · Cited by 11
Jiang, H., Huang, G., Zhao, N., Zhang, T., Jiang, M., He, Y., Zhou, X., & Jiang, X. (2018) · Figshare · doi:10.6084/m9.figshare.c.4178285 · Cited by 10
Subcellular Heterogeneity of the microRNA Machinery
Trabucchi, M., & Matégot, R. (2019) · Trends in Genetics · doi:10.1016/j.tig.2019.07.008 · Cited by 7
Low Expression of miR-424-3p is Highly Correlated with Clinical Failure in Prostate Cancer
Richardsen, E. H., Andersen, S., Al‐Saad, S., Tasken, K. T., Mills, M. I., & Busund, L. B. (2018) · European Urology Supplements · doi:10.1016/s1569-9056(18)33001-x · Cited by 6
Cited by
Trials and Tribulations of MicroRNA Therapeutics
Seyhan, A. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031469 · Cited by 381
MicroRNA as an Important Target for Anticancer Drug Development
Fu, Z., Wang, L., Li, S., Chen, F., Au-Yeung, K. K.-W., & Shi, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.736323 · Cited by 133
Postwala, H., Shah, Y., Parekh, P. S., & Chorawala, M. R. (2023) · Medical Oncology · doi:10.1007/s12032-023-02201-8 · Cited by 26
Recent Progress in Extracellular Vesicle-Based Carriers for Targeted Drug Delivery in Cancer Therapy
Tang, Y., Liu, X., Sun, M., Xiong, S., Xiao, N., Li, J., He, X., & Xie, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071902 · Cited by 24
Metabolic reprogramming: The driving force behind cancer drug resistance
El-Sehrawy, A. A. M. A., Hsu, C.-Y., Alkhathami, A. G., Chandra, M., Basunduwah, T. S., Malathi, H., Senapati, J. N., Gautam, A., Kadhem, M., & Yasin, H. A. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152392 · Cited by 11
Metadata
- Authors
- He, B., Zhao, Z., Cai, Q., Zhang, Y., Zhang, P., Shi, S., Xie, H., Peng, X., Yin, W., Tao, Y., & Wang, X.
- Venue
- International Journal of Biological Sciences
- Publisher
- Ivyspring International Publisher
- Published
- 2020
- Volume
- 16
- Issue
- 14
- Pages
- 2628-2647
- ISSN
- 1449-2288 (ISSN-L)
- OpenAlex
- W3044903507
- Cited by
- 625
- References
- 218
- FWCI
- 17.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.